ArticleThe oncologist2021

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.

Gary Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.